Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
| Market Capitalization | $14.8139 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.362 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.07 |
| EBITDA | -4,769.105 |
| Profit Margin | 0 |
| Operating Margin TTM | -4.911 |
| Return on Assets TTM | -0.1236 |
| Return on Equity TTM | -0.1768 |
| Revenue TTM | 971.655 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2019-06-30 | 0 | |||
| 2020-06-30 | 0 | |||
| 2021-06-30 | 0 | |||
| 2022-06-30 | 0 | 5,448.654 | ||
| 2023-06-30 | 3.08 | 3.076 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2020-06-30 | 1,146.72 | 1,329.02 | 329.11 | 0 | 3,854.144 | |
| 2021-06-30 | 27,111 | 27,609 | 536 | 0 | 7,500 | 33,063 |
| 2022-06-30 | 25,455.289 | 25,897.583 | 559.645 | 0 | 0 | 35,037.623 |
| 2023-06-30 | 21,396.46 | 22,379.02 | 497.35 | 0 | 35,037.62 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2020-06-30 | -352.214 | -649.984 | 550.016 | |||
| 2021-06-30 | -915.228 | -852.891 | 6,617.041 | 7,763.764 | ||
| 2022-06-30 | -6,837.589 | -3,966.15 | 17,691.525 | 7,763.764 | 25,455.289 | |
| 2023-06-30 | -4,174.414 | -4,255.46 | -4,058.83 | 25,455.289 | 21,396.461 |